Niamh Madigan | 05/11/2012
The proportion of clinical trials in Phase I has increased significantly in the last number of years. This coupled with a number of Phase III failures has put increased emphasis on making the right decision as early as possible. Nancy Widener, Executive Director, Clinical Science and Operations at Bristol Myers Squibb delivers practical tips on how to eliminate errors in early development, thus saving millions of dollars and years of research....
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
GenAI Life Science & Health 2025
September 1 - 3 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More